XT
QNCX icon

XTX Topco’s Quince Therapeutics QNCX Stock Holding History

XTX Topco’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-244
Closed -$4.95K – 4605
2026
Q1 		$4.95K Buy
244
+182
+294% +$36.5K ﹤0.01% 3751
2025
Q4 		$41.8K Buy
+62
New +$31.2K ﹤0.01% 2879
2025
Q3 		– Sell
-113
Closed -$37.4K – 3136
2025
Q2 		$37.4K Buy
+113
New +$25.8K ﹤0.01% 2072
2024
Q4 		– Sell
-108
Closed -$16.7K – 2818
2024
Q3 		$16.7K Buy
108
+38
+54% +$5.45K ﹤0.01% 1867
2024
Q2 		$10.6K Buy
+70
New +$12.6K ﹤0.01% 1685
2024
Q1 		– Sell
-107
Closed -$22.5K – 2230
2023
Q4 		$22.5K Sell
107
-53
-33% -$10.6K ﹤0.01% 1347
2023
Q3 		$35.8K Buy
+160
New +$41.8K 0.01% 1315

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco's QNCX Position: Q2 2026 in Review

XTX Topco sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 244 shares — an estimated $4.95K sold.

XTX Topco first reported a position in QNCX in Q3 2023 and held it in 7 quarters. The position peaked at $41.8K in Q4 2025. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • XTX Topco reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 244 Quince Therapeutics shares in Q2 2026, an estimated $4.95K.
  • XTX Topco first reported a position in Quince Therapeutics in Q3 2023 and held it in 7 quarters.
  • XTX Topco's Quince Therapeutics position peaked at $41.8K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.